Sun Pharmaceutical Industries has got an approval from US Food and Drug Administration for its abbreviated new drug application, Olanzapine orally disintegrating tablets.
Sun Pharma stated in a filing with the Bombay Stock Exchange, that the tablets are therapeutic equivalents of Eli Lilly's Zyprexa Zydis tablets. Olanzapine tablets have an annual sale of about $360 million in the US, and are indicated in the treatment of schizophrenia and bipolar disorder.
The latest approval follows the US health regulator's decision last week, to import Sun Pharma's anti-cancer drug Lipodox to meet the shortage of another similar medicine Doxil.
Shares of Sun Pharma closed 0.78% up, at Rs 550, on the Bombay Stock Exchange.
